← Back to Search

Antineoplastic Agent

Mitomycin C + Raindrop Near Vision Inlay for Presbyopia

Phase 4
Waitlist Available
Led By Michael J Endl, MD
Research Sponsored by Fichte, Endl & Elmer Eyecare
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

The objective of this study is to evaluate the Raindrop® Near Vision Inlay for the improvement of near vision in presbyopes treated with low dose, short duration Mitomycin C (MMC) during surgery and an extended low dose steroid regimen after surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Uncorrected Visual Acuity
Secondary outcome measures
Incidence of Corneal Reaction

Trial Design

1Treatment groups
Experimental Treatment
Group I: Mitomycin C + Raindrop Near Vision InlayExperimental Treatment2 Interventions
The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the Raindrop Near Vision Inlay in Presbyopes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mitomycin
FDA approved

Find a Location

Who is running the clinical trial?

Fichte, Endl & Elmer EyecareLead Sponsor
1 Previous Clinical Trials
18 Total Patients Enrolled
Michael J Endl, MDPrincipal InvestigatorFichte, Endl & Elmer Eyecare

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Apr 2025